Caribou has entered into key strategic partnerships with recognized leaders in our target market sectors that both support and validate our development efforts.
DuPont: Caribou has a strategic alliance with DuPont designed to advance the two organizations' respective CRISPR-derived genome editing technology platforms. The agreement includes the cross-licensing of key intellectual property, a research collaboration, and financial investments by DuPont in Caribou. Both companies control patent portfolios covering multiple foundational CRISPR-Cas technologies and the alliance enables Caribou to develop and utilize its technology for product development across a wide range of fields including human and animal therapeutics, diagnostics, industrial biotechnology, research tools, and certain agriculture segments. In addition, a multi-year research collaboration has been funded by DuPont which allows researchers from both organizations to share insights and work together to drive improvements to their respective platforms. DuPont was also an investor in Caribou's Series A financing round.
Genus: Caribou has entered a multi-year strategic collaboration with Genus under which Caribou has provided Genus with exclusive access to Caribou’s CRISPR-Cas9 technology for the development of new traits in pigs, cattle and potentially other livestock species. Among the first targets of the program is the further development and optimization of Genus’ Porcine Reproductive and Respiratory Syndrome Virus (“PRRSv”) resistant pigs. Caribou received an upfront payment from Genus and is eligible to receive regulatory and commercial milestone payments as well as royalties on licensed product sales. The partnership positions Caribou and Genus at the forefront of an emerging market for which CRISPR-Cas9 could have profound benefits to animal well-being and society. Genus was also an investor in Caribou's Series B financing round.
Intellia Therapeutics: In 2014, Caribou co-founded Intellia Therapeutics to develop curative medicines utilizing the Caribou CRISPR-Cas9 platform. Intellia has exclusive access to the platform for the development of new human gene and cell therapies as well as anti-viral therapies. Intellia is developing both ex vivo and in vivo applications of Caribou's gene editing technology. Near-term ex vivo applications include the treatment of blood disorders and cancer. Caribou retains full rights to pursue opportunities for its technology platform in other valuable therapeutic markets, with current areas of exploration in antimicrobials and animal health.
Novartis Institutes for Biomedical Research: Caribou has partnered with Novartis in a research program to develop the Caribou CRISPR-Cas9 platform for drug target screening and validation technologies. Novartis offers a diversified portfolio of products to address the needs of patients for innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines, and over-the-counter products. The advancement of the CRISPR-based platform for screening and validation will help further the development of new therapeutic products and will work orthogonally and in complement with current RNAi-based screening approaches which only work transiently and with low specificity. The Caribou CRISPR-based platform can utilize guide RNAs specific for unique sequences and target a gene at numerous sites and therefore provide enhanced specificity. In addition to the research collaboration, Novartis was an investor in Caribou's Series A financing round.
New Collaborations: In addition to our existing partnerships, we are always pursuing strategic opportunities that will allow us to expand our research and work together towards future breakthroughs. CRISPR-Cas technology has applications across the fields of biotechnology and we are open to working with prospective partners across the full breadth of the technology’s potential.